DC
Therapeutic Areas
Formycon AG Pipeline
| Drug | Indication | Phase |
|---|---|---|
| FYB201 | Ophthalmology (nAMD, DME, RVO, myopic CNV) | Approved |
| FYB202 | Immunology (Psoriasis, Psoriatic Arthritis, Crohn's, UC) | Phase III |
| FYB203 | Ophthalmology (nAMD, DME, RVO) | Phase III |
| FYB206 | Oncology (Pembrolizumab biosimilar) | Preclinical |
| FYB208 | Immunology (Dupilumab biosimilar) | Preclinical |
| FYB207 | HAE (Long-acting C1-esterase inhibitor) | Research |